BACKGROUND AND PURPOSE: The purpose of this review is to evaluate the methodology used in published phase I radiotherapy (RT) dose escalation trials. A specific emphasis was placed on the frequency of reporting late complications as endpoint. MATERIALS AND METHODS: We performed a systematic literature review using a predefined search strategy to identify all phase I trials reporting on external radiotherapy dose escalation in cancer patients. RESULTS: Fifty-three trials (phase I: n = 36, phase I-II: n = 17) fulfilled the inclusion criteria. Of these, 20 used a modified Fibonacci design for the RT dose escalation, but 32 did not specify a design. Late toxicity was variously defined as > 3 months (n = 43) or > 6 months (n = 3) after RT, or not defined (n = 7). In only nine studies the maximum tolerated dose (MTD) was related to late toxicity, while only half the studies reported the minimum follow-up period for dose escalation (n = 26). CONCLUSION: In phase I RT trials, late complications are often not taken into account and there is currently no consensus on the methodology used for radiation dose escalation studies. We therefore propose a decision-tree algorithm which depends on the endpoint selected and whether a validated early surrogate endpoint is available, in order to choose the most appropriate study design. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND AND PURPOSE: The purpose of this review is to evaluate the methodology used in published phase I radiotherapy (RT) dose escalation trials. A specific emphasis was placed on the frequency of reporting late complications as endpoint. MATERIALS AND METHODS: We performed a systematic literature review using a predefined search strategy to identify all phase I trials reporting on external radiotherapy dose escalation in cancerpatients. RESULTS: Fifty-three trials (phase I: n = 36, phase I-II: n = 17) fulfilled the inclusion criteria. Of these, 20 used a modified Fibonacci design for the RT dose escalation, but 32 did not specify a design. Late toxicity was variously defined as > 3 months (n = 43) or > 6 months (n = 3) after RT, or not defined (n = 7). In only nine studies the maximum tolerated dose (MTD) was related to late toxicity, while only half the studies reported the minimum follow-up period for dose escalation (n = 26). CONCLUSION: In phase I RT trials, late complications are often not taken into account and there is currently no consensus on the methodology used for radiation dose escalation studies. We therefore propose a decision-tree algorithm which depends on the endpoint selected and whether a validated early surrogate endpoint is available, in order to choose the most appropriate study design. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: Johan Bussink; Johannes H A M Kaanders; Winette T A van der Graaf; Wim J G Oyen Journal: Nat Rev Clin Oncol Date: 2011-01-25 Impact factor: 66.675
Authors: Ricky A Sharma; Ruth Plummer; Julie K Stock; Tessa A Greenhalgh; Ozlem Ataman; Stephen Kelly; Robert Clay; Richard A Adams; Richard D Baird; Lucinda Billingham; Sarah R Brown; Sean Buckland; Helen Bulbeck; Anthony J Chalmers; Glen Clack; Aaron N Cranston; Lars Damstrup; Roberta Ferraldeschi; Martin D Forster; Julian Golec; Russell M Hagan; Emma Hall; Axel-R Hanauske; Kevin J Harrington; Tom Haswell; Maria A Hawkins; Tim Illidge; Hazel Jones; Andrew S Kennedy; Fiona McDonald; Thorsten Melcher; James P B O'Connor; John R Pollard; Mark P Saunders; David Sebag-Montefiore; Melanie Smitt; John Staffurth; Ian J Stratford; Stephen R Wedge Journal: Nat Rev Clin Oncol Date: 2016-06-01 Impact factor: 66.675
Authors: R de Haan; E van Werkhoven; M M van den Heuvel; H M U Peulen; G S Sonke; P Elkhuizen; M W M van den Brekel; M E T Tesselaar; C Vens; J H M Schellens; B van Triest; M Verheij Journal: BMC Cancer Date: 2019-09-10 Impact factor: 4.430